Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER) finds Prostate cancer screening has little benefit for men aged 75 and older, yet over three years, the Medicare fee-for-service program spent $447 million annually on PSA-based screenings – one-third of which was for men in the over 75 age group.
